1088P - Effect of 13q deletion on IL-6 production in patients with multiple myeloma

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Myeloproliferative Neoplasms
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Tarek Yakout
Authors T. Yakout1, H.A. Azim2, N.M. Kassem2, R.H. Khalifa3
  • 1Medical Oncology, Cairo Oncology Center -CairoCure, 12311 - Cairo/EG
  • 2Clinical Oncology Department (nemrock), Faculty of Medicine, Cairo University, 11435 - Cairo/EG
  • 3Clinical Pathology, Kasr Al-Aini Hospital, Cairo/EG



Numerous studies have shown a correlation between 13q deletion and poor prognosis in multiple myeloma (MM), but the mechanisms are not fully understood. Earlier studies suggest that this lesion involves large segments or the entire long arm involving the retinoblastoma (Rb) gene. In myeloma, Rb gene is believed to downregulate interleukin -6 (IL-6) which plays a central role in the pathogenesis of MM. Therefore, it has been hypothesized that loss of Rb gene might be associated with very high expression of IL-6 and subsequent bad prognosis.

Materials and methods

Forty MM patients and 20 matched controls were included in this study. Interphase fluorescence in situ hybridization (FISH) analysis was performed using LSI 13q14-specific probe. Serum levels of IL-6 were determined by ELISA. All patients received conventional chemotherapy. Refractory patients received other therapeutic regimen of Thalidomide or Bortezomib.


Significant increase (p < 0.001) of IL-6 production was recorded in patients with 13q deletion compared to patients with normal chromosome 13q status .These patients were also refractory to conventional chemotherapy but showed striking response to Thalidomide or Bortezomib.


This study suggests that 13q deletions are associated with increased production of IL-6 in MM and this could be a possible cause of the associated bad prognosis. In addition, the results also show the potential to improve responses in patients with refractory MM with the introduction of novel therapies.


All authors have declared no conflicts of interest.